Citadel Advisors
CSTL icon

Citadel Advisors’s Castle Biosciences CSTL Stock Holding History

Citadel Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$307K Buy
+12,500
New +$409K ﹤0.01% 10420
2025
Q4 		– Sell
-9,300
Closed -$212K – 12839
2025
Q3 		$212K Buy
+9,300
New +$189K ﹤0.01% 11150
2025
Q2 		– Sell
-5,000
Closed -$100K – 12892
2025
Q1 		$100K Sell
5,000
-3,300
-40% -$81.7K ﹤0.01% 11463
2024
Q4 		$221K Buy
8,300
+2,400
+41% +$73.1K ﹤0.01% 10269
2024
Q3 		$168K Buy
5,900
+5,800
+5,800% +$148K ﹤0.01% 10404
2024
Q2 		$2.18K Buy
+100
New +$2.23K ﹤0.01% 13722
2024
Q1 		– Sell
-3,500
Closed -$75.5K – 14668
2023
Q4 		$75.5K Sell
3,500
-3,200
-48% -$56.3K ﹤0.01% 11290
2023
Q3 		$113K Buy
6,700
+5,600
+509% +$97.9K ﹤0.01% 10736
2023
Q2 		$15.1K Buy
1,100
+900
+450% +$18.2K ﹤0.01% 12965
2023
Q1 		$4.54K Sell
200
-5,900
-97% -$144K ﹤0.01% 13947
2022
Q4 		$144K Buy
+6,100
New +$141K ﹤0.01% 10674
2021
Q2 		– Sell
-4,800
Closed -$329K – 13756
2021
Q1 		$329K Sell
4,800
-7,500
-61% -$564K ﹤0.01% 10620
2020
Q4 		$826K Buy
12,300
+6,600
+116% +$358K ﹤0.01% 7190
2020
Q3 		$293K Buy
+5,700
New +$254K ﹤0.01% 8169

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's CSTL Position: Q1 2026 in Review

Citadel Advisors reduced its Castle Biosciences (CSTL) stake by 67% in Q1 2026, selling an estimated $8.04M and leaving 120,977 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #5285.

Citadel Advisors first reported a position in CSTL in Q3 2019 and has held it in 26 quarters since. The position peaked at $22.2M in Q4 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Citadel Advisors held 120,977 shares of Castle Biosciences worth $2.97M as of Q1 2026.
  • Citadel Advisors sold 245,379 Castle Biosciences shares in Q1 2026, an estimated $8.04M.
  • Castle Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5285 holding.
  • Citadel Advisors first reported a position in Castle Biosciences in Q3 2019 and has held it in 26 quarters since.
  • Citadel Advisors's Castle Biosciences position peaked at $22.2M in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.